| EDUCATION FORUM |
|
| Year : 2006 | Volume
: 38
| Issue : 1 | Page : 5-12 |
Screening of antimalarial drugs: An overview
BS Kalra1, S Chawla1, P Gupta1, N Valecha2
1 Department of Pharmacology, Maulana Azad Medical College, Bahadur Shah Zafar Marg, Delhi- 110002, India
2 Malaria Research Center, No. 22, Sham Nath Marg, Delhi- 110054, India
Correspondence Address:
B S Kalra
Department of Pharmacology, Maulana Azad Medical College, Bahadur Shah Zafar Marg, Delhi- 110002
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.19846
Efforts to discover and develop new antimalarial drugs have increased dramatically in recent years mainly because of resistance to existing antimalarial drugs. Selection of candidate drugs for clinical trials in man and the design of clinical protocols are based upon consideration of data from a battery of preclinical test systems. All compounds are assessed initially in one or more primary screening models. A compound which is considered 'active' by well established criteria in primary screening test is considered for further evaluation in successively more clinical tests. At the end of each stage of testing, a decision is taken to advance the compound to the next stage or discontinue it. Primary screening tests should have optimal sensitivity, a high degree of reproducibility, high throughput, requiring a minimum quantity of test compound and should bear low cost. As there is growing need for newer and more efficacious antimalarial drugs especially in tropical countries, more sensitive and economical screening models are needed. This review is an update of various conventional and latest in vitro and in vivo screening methods being used for evaluation of antimalarial compounds.
[FULL TEXT] [PDF]*
|
